SAN DIEGO--(BUSINESS WIRE)--Aug. 22, 2018-- DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today that it has acquired TypeZero Technologies, Inc. (“TypeZero”). TypeZero’s offering includes the inControl diabetes management system, designed to provide personalized diabetes management solutions including technology to automatically adjust and regulate insulin delivery.
Dexcom, TypeZero and the University of Virginia have had a longstanding, productive relationship in developing important technologies for diabetes management, including inControl for integration with both automated insulin delivery (“AID”) and smart pens. The companies share a consistent vision to improve the lives of people with diabetes through innovation.
“As the first iCGM designated by the FDA, Dexcom again has the opportunity to lead the market for integrated systems for diabetes management. TypeZero is a great fit for Dexcom as we look to deliver a growing set of tools to both our insulin delivery partners and our customers,” said Steve Pacelli, Dexcom’s Executive Vice President of Strategy & Corporate Development. “Combined with best-in-class CGM technology, we believe TypeZero’s technology and strong team will accelerate our efforts to further differentiate Dexcom’s portfolio.”
“The TypeZero team is excited for our next chapter as part of Dexcom,” said Chad Rogers, TypeZero’s CEO. “For the last several years, our company has been committed to creating diabetes management products that simplify the life of a person with diabetes. As part of Dexcom, we will continue to embrace the mission to empower people with diabetes through innovation.”
Dexcom currently expects to support the first commercial launch of an AID system using the inControl algorithm in 2019.
The terms of the transaction were not disclosed.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) systems for use by people with diabetes and healthcare providers. With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked DexCom highest in customer satisfaction and loyalty. For more information on the Dexcom CGM, visit www.dexcom.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180822005550/en/
Source: DexCom, Inc.
Steve Pacelli, 858-200-0200
First and only single-use, professional CGM system with blinded or unblinded mode
Dexcom, Inc. (NASDAQ:DXCM) announced today the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G6 Pro Continuous Glucose Monitoring (CGM)...
Join Dexcom at the upcoming AADE conference from August 9-12, 2019, in Houston, TX. Attendees are invited to attend a special Dexcom product theater and participate in the Dexcom DANA Technology Workshop (details for both...
The ATDC conference will be held on July 11-14, 2019 in Keystone, CO. This event will focus on using new technologies to overcome challenges in day-to-day management of diabetes. Clinical studies and the benefits of Dexcom...